{"id":"W2793000301","doi":"10.1158/1538-7445.sabcs17-gs3-03","title":"Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical endpoint; Celecoxib; Placebo; Breast cancer; Internal medicine; Hazard ratio; Proportional hazards model; Cancer; Oncology; Clinical trial; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002638238,0.002674055,0.004308361,0.0006278516,0.0005388483,0.001656142,0.001180863,0.00252228,0.01704437],"category_scores_gemma":[0.002193695,0.0007860883,0.002181803,0.000809818,0.001869563,0.001149851,0.0006040438,0.003116722,0.002124094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000926263,"about_ca_system_score_gemma":0.001567082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001103443,"about_ca_topic_score_gemma":0.002402494,"domain_scores_codex":[0.9990155,0.0005783928,0.00005904795,0.0001480809,0.00006020292,0.0001386998],"domain_scores_gemma":[0.9991334,0.0001903711,0.0002479318,0.00007476827,0.00006311709,0.0002904297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9912478,0.002043766,0.0001537067,0.0005246635,0.0003613454,0.00001951309,0.00001592898,0.0001175418,0.0009997615,0.00007898951,0.0006812784,0.003755627],"study_design_scores_gemma":[0.9849014,0.01413096,0.0003365681,0.00001454268,0.0001178829,0.00001047369,0.000005850025,0.00006947326,0.0000748021,0.00006717724,0.0002666191,0.000004362441],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9505508,0.01445254,0.001429301,0.002635951,0.002540533,0.01706742,0.005141079,0.000593619,0.005588812],"genre_scores_gemma":[0.9523478,0.005634408,0.002533702,0.003894783,0.001663233,0.02145541,0.002913425,0.00008595976,0.009471315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01704437,"threshold_uncertainty_score":0.05701905,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08332244430336941,"score_gpt":0.4029894656007412,"score_spread":0.3196670212973718,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}